OMC
SPRO icon

Oasis Management Company’s Spero Therapeutics SPRO Stock Holding History

Oasis Management Company’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-288,000
Closed -$498K – 106
2022
Q4 		$498K Hold
288,000
– – 0.1% 68
2022
Q3 		$576K Hold
288,000
– – 0.1% 78
2022
Q2 		$213K Buy
+288,000
New +$838K 0.04% 109

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Oasis Management Company's SPRO Position: Q1 2023 in Review

Oasis Management Company sold out of Spero Therapeutics (SPRO) in Q1 2023, closing a stake of 288,000 shares — an estimated $498K sold.

Oasis Management Company first reported a position in SPRO in Q2 2022 and held it in 3 quarters. The position peaked at $576K in Q3 2022. 48 funds tracked by Wall St. Rank hold SPRO as of Q1 2023.

  • Oasis Management Company reported no remaining Spero Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Oasis Management Company sold 288,000 Spero Therapeutics shares in Q1 2023, an estimated $498K.
  • Oasis Management Company first reported a position in Spero Therapeutics in Q2 2022 and held it in 3 quarters.
  • Oasis Management Company's Spero Therapeutics position peaked at $576K in Q3 2022.
  • 48 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2023.

Based on Oasis Management Company's 13F filing for Q1 2023, filed 15 May 2023.